Medivation

medivation.com

Medivation Inc., which is now a part of Pfizer, Inc. is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS

FogPharma | November 28, 2022

news image

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset...

Read More

Business Insights

TO PROVIDE SUITE OF CLINICAL TRIAL TECHNOLOGIES AND SERVICES, LABCORP RENEWED STRATEGIC PARTNERSHIP WITH MEDIDATA

Medidata | April 01, 2022

news image

A Dassault Systèmes company, Medidata, announced that Labcorp, a leading global life sciences company, has extended its 14-year partnership with Medidata, laying the groundwork for their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials. “Our relationship with Medidata is built on using their core technologies to enhance our clinical trial portfolio and continue to expand our decentr...

Read More

Research, PHARMA TECH

BIOCYTOGEN ANNOUNCES NON-EXCLUSIVE LICENSE AGREEMENT WITH JANSSEN BIOTECH

Biocytogen | March 09, 2023

news image

On March 8, 2023, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The deal was facilitated by Johnson & Johnson Innovation LLC. Under the agreement, Janssen and its affiliates have been granted a global, non-exclusive license to utilize Biocytogen's RenLite® platform and its underlying intellectual propert...

Read More

Business Insights

SEAGEN AND SANOFI ANNOUNCED PARTNERSHIP FOR THE DEVELOPMENT AND COMMERCIALIZATION OF MULTIPLE NOVEL ANTIBODY-DRUG CONJUGATES

Seagen Inc. | March 17, 2022

news image

Sanofi and Seagen signed an exclusive partnership agreement to discover, develop, and market antibody-drug conjugates targeting three cancer targets. Sanofi's patented monoclonal antibody technology and Seagen's proprietary ADC technology will be used. Sanofi presently has one ADC under development, an antibody designed to deliver strong anti-cancer medications to tumor cells expressing a particular protein. “We are excited to be working with Sa...

Read More
news image

Pharmacy Market

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS

FogPharma | November 28, 2022

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset...

Read More
news image

Business Insights

TO PROVIDE SUITE OF CLINICAL TRIAL TECHNOLOGIES AND SERVICES, LABCORP RENEWED STRATEGIC PARTNERSHIP WITH MEDIDATA

Medidata | April 01, 2022

A Dassault Systèmes company, Medidata, announced that Labcorp, a leading global life sciences company, has extended its 14-year partnership with Medidata, laying the groundwork for their initiative to co-develop digital biomarkers and expand the use and functionality of decentralized clinical trials. “Our relationship with Medidata is built on using their core technologies to enhance our clinical trial portfolio and continue to expand our decentr...

Read More
news image

Research, PHARMA TECH

BIOCYTOGEN ANNOUNCES NON-EXCLUSIVE LICENSE AGREEMENT WITH JANSSEN BIOTECH

Biocytogen | March 09, 2023

On March 8, 2023, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The deal was facilitated by Johnson & Johnson Innovation LLC. Under the agreement, Janssen and its affiliates have been granted a global, non-exclusive license to utilize Biocytogen's RenLite® platform and its underlying intellectual propert...

Read More
news image

Business Insights

SEAGEN AND SANOFI ANNOUNCED PARTNERSHIP FOR THE DEVELOPMENT AND COMMERCIALIZATION OF MULTIPLE NOVEL ANTIBODY-DRUG CONJUGATES

Seagen Inc. | March 17, 2022

Sanofi and Seagen signed an exclusive partnership agreement to discover, develop, and market antibody-drug conjugates targeting three cancer targets. Sanofi's patented monoclonal antibody technology and Seagen's proprietary ADC technology will be used. Sanofi presently has one ADC under development, an antibody designed to deliver strong anti-cancer medications to tumor cells expressing a particular protein. “We are excited to be working with Sa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us